Swanson Linnea, Kassab Ihab, Tsung Irene, Worden Francis P, Fontana Robert J
Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Division of Hematology & Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
Immunotherapy. 2022 Apr;14(6):409-418. doi: 10.2217/imt-2021-0191. Epub 2022 Mar 2.
To describe the incidence and outcomes of liver injury in patients with advanced cutaneous squamous cell carcinoma (cSCC) receiving cemiplimab. Charts of cSCC patients receiving cemiplimab between 28 September 2018 and 14 July 2020 were reviewed. Liver injury was determined using laboratory criteria, and causality assessment was completed. Of 39 cemiplimab-treated patients, four (10.3%) developed liver injury. Two cases of hepatotoxicity were attributed to immune-mediated liver injury caused by cemiplimab and the two other cases were attributed to other causes. The four patients with liver injury had tumor responses and survival similar to those of the patients without liver injury. Liver injury arising during cemiplimab therapy is mild and infrequent in cSCC patients. Due to its favorable safety profile, cemiplimab should be considered in patients with cSCC and pre-existing liver disease.
描述接受西米普利单抗治疗的晚期皮肤鳞状细胞癌（cSCC）患者肝损伤的发生率和结局。回顾了2018年9月28日至2020年7月14日期间接受西米普利单抗治疗的cSCC患者的病历。使用实验室标准确定肝损伤，并完成因果关系评估。在39例接受西米普利单抗治疗的患者中，4例（10.3%）发生了肝损伤。2例肝毒性归因于西米普利单抗引起的免疫介导性肝损伤，另外2例归因于其他原因。4例肝损伤患者的肿瘤反应和生存率与无肝损伤患者相似。西米普利单抗治疗期间出现的肝损伤在cSCC患者中较轻且不常见。由于其良好的安全性，对于患有cSCC和既往有肝病的患者，应考虑使用西米普利单抗。
